Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Prognos Achieves HITRUST CSF® Certification to Further Mitigate Risk in Third Party Privacy, Security and Compliance

Posted on: 24 Feb 18

NEW YORK, Feb. 22, 2018 /PRNewswire/ -- Prognos, an innovator in predicting disease by applying artificial intelligence (AI) to clinical lab diagnostics, today announced that Prognos payer product portfolio, featuring DxCloud, Care Alerts, Care Gaps, and Risk Alerts, has earned Certified status for information security by HITRUST.

HITRUST CSF Certified status demonstrates that the organization's payer product portfolio has met key regulations and industry-defined requirements and is appropriately managing risk. This achievement places Prognos in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the HITRUST CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

"Prognos strives to be a good custodian of data entrusted to us and a reliable partner to our payer clients, so we viewed the HITRUST CSF Certification as a must-have for our payer solutions," said Sundeep Bhan, Cofounder and CEO of Prognos. "By earning the HITRUST CSF Certification for DxCloud, Care Alerts, Care Gaps, and Risk Alerts, we demonstrated that these products comply with the security requirements inherent in HIPAA to safeguard protected health information."

Prognos DxCloud is an end-to-end solution to solve data connectivity, quality and analytics needs. Prognos transforms lab data into actionable insights that allow payers to intelligently manage data.

Prognos Care Alerts and Care Gaps provide an early alert system for chronic disease identification and management. Actionable analytics direct interventions for decreased utilization and increased quality scores.

Prognos Risk Alerts provide longitudinal member views based on lab results to better facilitate care and steer members to disease management, providing a better understanding of specific disease profiles, early insight into exchange populations, and insight into new member diagnoses to drive risk adjustment payments.

"HITRUST has been working with the industry to ensure the appropriate information protection requirements are met when sensitive information is accessed or stored in a cloud environment. By taking the steps necessary to obtain HITRUST CSF Certified status, Prognos is distinguished as an organization that people can count on to keep their information safe," said Ken Vander Wal, Chief Compliance Officer, HITRUST.

About Prognos

Prognos is a healthcare AI company focused on predicting disease to drive decisions earlier in healthcare in collaboration with payers, Life Sciences and diagnostics companies. The Prognos Registry is the largest source of clinical diagnostics information in 50 disease areas, with over 14B medical records for 180M patients. Prognos has 1,000 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. The company is supported by a $42M investment from Safeguard Scientifics, Inc. (SFE), Merck Global Health Innovation Fund (GHIF), Cigna (CI), GIS Strategic Ventures, Hikma Ventures, Hermed Capital, and Maywic Select Investments. For more information, visit

Prognos Media Contact:

Yuliya Kutuzava
KNB Communications
P: (203) 504-8230, ext. 131

Editor's Details

Mike Wood

Last updated on: 24/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.